{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T21:21:06Z","timestamp":1793654466121,"version":"4.5.1"},"reference-count":51,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,10,1]],"date-time":"2020-10-01T00:00:00Z","timestamp":1601510400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,10,1]],"date-time":"2020-10-01T00:00:00Z","timestamp":1601510400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004085","name":"Ministry of Education, Science and Technology","doi-asserted-by":"publisher","award":["NRF-2015R1A5A2008833"],"award-info":[{"award-number":["NRF-2015R1A5A2008833"]}],"id":[{"id":"10.13039\/501100004085","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004085","name":"Ministry of Education, Science and Technology","doi-asserted-by":"publisher","award":["NRF-2018R1D1A1A02047809"],"award-info":[{"award-number":["NRF-2018R1D1A1A02047809"]}],"id":[{"id":"10.13039\/501100004085","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004085","name":"Ministry of Education, Science and Technology","doi-asserted-by":"publisher","award":["NRF-2018R1D1A1B07048818"],"award-info":[{"award-number":["NRF-2018R1D1A1B07048818"]}],"id":[{"id":"10.13039\/501100004085","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biomaterials"],"published-print":{"date-parts":[[2020,10]]},"DOI":"10.1016\/j.biomaterials.2020.120250","type":"journal-article","created":{"date-parts":[[2020,7,21]],"date-time":"2020-07-21T05:31:24Z","timestamp":1595309484000},"page":"120250","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":19,"special_numbering":"C","title":["Genetic engineering of novel super long-acting Exendin-4 chimeric protein for effective treatment of metabolic and cognitive complications of obesity"],"prefix":"10.1016","volume":"257","author":[{"given":"Jong Youl","family":"Lee","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taehoon","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eunmi","family":"Hong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reeju","family":"Amatya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyung-Ah","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Young-Hoon","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyoung Ah","family":"Min","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minki","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sumi","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seungmi","family":"Hwang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gu Seob","family":"Roh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meong Cheol","family":"Shin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.biomaterials.2020.120250_bib1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0167-0115(96)00135-8","article-title":"Bioactive peptides from lizard venoms","volume":"61","author":"Raufman","year":"1996","journal-title":"Regul. Pept."},{"issue":"4","key":"10.1016\/j.biomaterials.2020.120250_bib2","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1016\/j.toxicon.2010.12.016","article-title":"The development of Byetta (exenatide) from the venom of the Gila monster as an anti-diabetic agent","volume":"59","author":"Furman","year":"2012","journal-title":"Toxicon"},{"key":"10.1016\/j.biomaterials.2020.120250_bib3","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1007\/s40005-019-00433-3","article-title":"Injectable hydrogels for islet transplantation: a concise review","volume":"50","author":"Shrestha","year":"2020","journal-title":"J. Pharm. Investig."},{"issue":"1","key":"10.1016\/j.biomaterials.2020.120250_bib4","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.jphs.2018.08.009","article-title":"C-terminal site-specific PEGylated Exendin-4 analog: a long-acting glucagon like Peptide-1 receptor agonist, on glycemic control and beta cell function in diabetic db\/db mice","volume":"138","author":"Tang","year":"2018","journal-title":"J. Pharmacol. Sci."},{"issue":"2","key":"10.1016\/j.biomaterials.2020.120250_bib5","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1021\/bc049735+","article-title":"Synthesis, characterization, and pharmacokinetic studies of PEGylated glucagon-like peptide-1","volume":"16","author":"Lee","year":"2005","journal-title":"Bioconjugate Chem."},{"key":"10.1016\/j.biomaterials.2020.120250_bib6","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1016\/j.ejmech.2018.03.050","article-title":"Engineering a novel protease-based Exendin-4 derivative for type 2 antidiabetic therapeutics","volume":"150","author":"Zhong","year":"2018","journal-title":"Eur. J. Med. Chem."},{"issue":"2","key":"10.1016\/j.biomaterials.2020.120250_bib7","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0087704","article-title":"Novel exenatide analogs with peptidic albumin binding domains: potent anti-diabetic agents with extended duration of action","volume":"9","author":"Levy","year":"2014","journal-title":"PloS One"},{"issue":"2","key":"10.1016\/j.biomaterials.2020.120250_bib8","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1016\/j.bbrc.2014.02.045","article-title":"A novel exendin-4 human serum albumin fusion protein, E2HSA, with an extended half-life and good glucoregulatory effect in healthy rhesus monkeys","volume":"445","author":"Zhang","year":"2014","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"14","key":"10.1016\/j.biomaterials.2020.120250_bib9","doi-asserted-by":"crossref","first-page":"4121","DOI":"10.1016\/j.biomaterials.2010.01.091","article-title":"Long acting hyaluronate--exendin 4 conjugate for the treatment of type 2 diabetes","volume":"31","author":"Kong","year":"2010","journal-title":"Biomaterials"},{"issue":"11","key":"10.1016\/j.biomaterials.2020.120250_bib10","doi-asserted-by":"crossref","first-page":"2834","DOI":"10.1016\/j.biomaterials.2013.01.013","article-title":"A long-acting formulation of a polypeptide drug exenatide in treatment of diabetes using an injectable block copolymer hydrogel","volume":"34","author":"Li","year":"2013","journal-title":"Biomaterials"},{"issue":"3","key":"10.1016\/j.biomaterials.2020.120250_bib11","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1016\/j.jconrel.2012.05.029","article-title":"Self-assembled glycol chitosan nanogels containing palmityl-acylated exendin-4 peptide as a long-acting anti-diabetic inhalation system","volume":"161","author":"Lee","year":"2012","journal-title":"J. Contr. Release"},{"issue":"5","key":"10.1016\/j.biomaterials.2020.120250_bib12","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1007\/s40262-015-0338-3","article-title":"Clinical pharmacokinetics of dulaglutide in patients with type 2 diabetes: analyses of data from clinical trials","volume":"55","author":"Geiser","year":"2016","journal-title":"Clin. Pharmacokinet."},{"issue":"12","key":"10.1016\/j.biomaterials.2020.120250_bib13","doi-asserted-by":"crossref","first-page":"4810","DOI":"10.1210\/jc.2008-1518","article-title":"Pharmacodynamics, pharmacokinetics, safety, and tolerability of albiglutide, a long-acting glucagon-like peptide-1 mimetic, in patients with type 2 diabetes","volume":"93","author":"Matthews","year":"2008","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"2","key":"10.1016\/j.biomaterials.2020.120250_bib14","first-page":"1","article-title":"Distribution and elimination of protein therapeutics: a review","volume":"4","author":"Sutradhar","year":"2011","journal-title":"Stamford J. Pharm. Sci."},{"issue":"1\u20132","key":"10.1016\/j.biomaterials.2020.120250_bib15","first-page":"81","article-title":"Elimination mechanisms of therapeutic monoclonal antibodies, Drug Discov","volume":"11","author":"Tabrizi","year":"2006","journal-title":"Today Off."},{"issue":"3","key":"10.1016\/j.biomaterials.2020.120250_bib16","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1038\/ki.1979.128","article-title":"Renal filtration, transport, and metabolism of low-molecular-weight proteins: a review","volume":"16","author":"Maack","year":"1979","journal-title":"Kidney Int."},{"issue":"6","key":"10.1016\/j.biomaterials.2020.120250_bib17","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1016\/j.copbio.2011.06.012","article-title":"Strategies for extended serum half-life of protein therapeutics","volume":"22","author":"Kontermann","year":"2011","journal-title":"Curr. Opin. Biotechnol."},{"key":"10.1016\/j.biomaterials.2020.120250_bib18","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/j.jconrel.2019.02.016","article-title":"Current strategies in extending half-lives of therapeutic proteins","volume":"301","author":"Zaman","year":"2019","journal-title":"J. Contr. Release"},{"key":"10.1016\/j.biomaterials.2020.120250_bib19","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1007\/s40005-019-00449-9","article-title":"Long acting injectable formulations: the state of the arts and challenges of poly (lactic-co-glycolic acid) microsphere, hydrogel, organogel and liquid crystal","volume":"49","author":"Lee","year":"2019","journal-title":"J. Pharm. Investig."},{"issue":"12","key":"10.1016\/j.biomaterials.2020.120250_bib20","doi-asserted-by":"crossref","first-page":"5526","DOI":"10.1016\/j.bbagen.2013.04.023","article-title":"Albumin as a versatile platform for drug half-life extension","volume":"1830","author":"Sleep","year":"2013","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.biomaterials.2020.120250_bib21","doi-asserted-by":"crossref","first-page":"682","DOI":"10.3389\/fimmu.2014.00682","article-title":"Unraveling the interaction between FcRn and albumin: opportunities for design of albumin-based therapeutics","volume":"5","author":"Sand","year":"2015","journal-title":"Front. Immunol."},{"issue":"48","key":"10.1016\/j.biomaterials.2020.120250_bib22","doi-asserted-by":"crossref","first-page":"17110","DOI":"10.1073\/pnas.1417717111","article-title":"An engineered affibody molecule with pH-dependent binding to FcRn mediates extended circulatory half-life of a fusion protein","volume":"111","author":"Seijsing","year":"2014","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"issue":"10","key":"10.1016\/j.biomaterials.2020.120250_bib23","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1093\/protein\/gzv040","article-title":"Fusion to a highly stable consensus albumin binding domain allows for tunable pharmacokinetics","volume":"28","author":"Jacobs","year":"2015","journal-title":"Protein Eng. Des. Sel."},{"issue":"28","key":"10.1016\/j.biomaterials.2020.120250_bib24","doi-asserted-by":"crossref","first-page":"13388","DOI":"10.1016\/S0021-9258(19)76438-2","article-title":"Definition of IgG-and albumin-binding regions of streptococcal protein G","volume":"262","author":"Akerstr\u00f6m","year":"1987","journal-title":"J. Biol. Chem."},{"issue":"8","key":"10.1016\/j.biomaterials.2020.120250_bib25","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1038\/nbt0897-772","article-title":"Binding proteins selected from combinatorial libraries of an \u03b1-helical bacterial receptor domain","volume":"15","author":"Nord","year":"1997","journal-title":"Nat. Biotechnol."},{"issue":"12","key":"10.1016\/j.biomaterials.2020.120250_bib26","doi-asserted-by":"crossref","first-page":"2670","DOI":"10.1016\/j.febslet.2010.04.014","article-title":"Affibody molecules: engineered proteins for therapeutic, diagnostic and biotechnological applications","volume":"584","author":"Lofblom","year":"2010","journal-title":"FEBS Lett."},{"issue":"5","key":"10.1016\/j.biomaterials.2020.120250_bib27","first-page":"846","article-title":"111In-benzyl-DTPA\u2013ZHER2: 342, an affibody-based conjugate for in vivo imaging of HER2 expression in malignant tumors","volume":"47","author":"Tolmachev","year":"2006","journal-title":"J. Nucl. Med."},{"issue":"6","key":"10.1016\/j.biomaterials.2020.120250_bib28","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1007\/s40005-019-00426-2","article-title":"Characterization of crosslinked hard gelatin capsules for a structural assembly of elementary osmotic pump delivery system","volume":"49","author":"Monton","year":"2019","journal-title":"J. Pharm. Investig."},{"issue":"6","key":"10.1016\/j.biomaterials.2020.120250_bib29","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.2337\/db11-1498","article-title":"Resveratrol attenuates obesity-associated peripheral and central inflammation and improves memory deficit in mice fed a high-fat diet","volume":"61","author":"Jeon","year":"2012","journal-title":"Diabetes"},{"issue":"4","key":"10.1016\/j.biomaterials.2020.120250_bib30","doi-asserted-by":"crossref","first-page":"262","DOI":"10.4093\/dmj.2012.36.4.262","article-title":"GLP-1 receptor agonist and non-alcoholic fatty liver disease","volume":"36","author":"Lee","year":"2012","journal-title":"Diabetes Metab. J."},{"issue":"2","key":"10.1016\/j.biomaterials.2020.120250_bib31","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1038\/nprot.2006.116","article-title":"Morris water maze: procedures for assessing spatial and related forms of learning and memory","volume":"1","author":"Vorhees","year":"2006","journal-title":"Nat. Protoc."},{"issue":"2","key":"10.1016\/j.biomaterials.2020.120250_bib32","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.regpep.2003.10.028","article-title":"Pharmacology of exenatide (synthetic exendin-4): a potential therapeutic for improved glycemic control of type 2 diabetes","volume":"117","author":"Nielsen","year":"2004","journal-title":"Regul. Pept."},{"issue":"4","key":"10.1016\/j.biomaterials.2020.120250_bib33","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1517\/14728214.2011.616493","article-title":"Emerging GLP-1 receptor agonists","volume":"16","author":"Lund","year":"2011","journal-title":"Expet Opin. Emerg. Drugs"},{"key":"10.1016\/j.biomaterials.2020.120250_bib34","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1007\/s40005-019-00440-4","article-title":"Medicinal plants and phytochemicals for diabetes mellitus: pharmacokinetic characteristics and herb-drug interactions","volume":"49","author":"Han","year":"2019","journal-title":"J. Pharm. Investig."},{"issue":"3","key":"10.1016\/j.biomaterials.2020.120250_bib35","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.nut.2009.07.008","article-title":"Exenatide and weight loss","volume":"26","author":"Bradley","year":"2010","journal-title":"Nutrition"},{"key":"10.1016\/j.biomaterials.2020.120250_bib36","doi-asserted-by":"crossref","first-page":"119474","DOI":"10.1016\/j.biomaterials.2019.119474","article-title":"Nanomaterials for the theranostics of obesity","volume":"223","author":"Li","year":"2019","journal-title":"Biomaterials"},{"issue":"1","key":"10.1016\/j.biomaterials.2020.120250_bib37","doi-asserted-by":"crossref","first-page":"E155","DOI":"10.1152\/ajpendo.2001.281.1.E155","article-title":"Exendin-4 reduces fasting and postprandial glucose and decreases energy intake in healthy volunteers","volume":"281","author":"Edwards","year":"2001","journal-title":"Am. J. Physiol. Endocrinol. Metab."},{"issue":"8","key":"10.1016\/j.biomaterials.2020.120250_bib38","doi-asserted-by":"crossref","first-page":"3103","DOI":"10.1210\/en.2011-0174","article-title":"Peripheral and central GLP-1 receptor populations mediate the anorectic effects of peripherally administered GLP-1 receptor agonists, liraglutide and exendin-4","volume":"152","author":"Kanoski","year":"2011","journal-title":"Endocrinol"},{"issue":"4","key":"10.1016\/j.biomaterials.2020.120250_bib39","doi-asserted-by":"crossref","first-page":"G920","DOI":"10.1152\/ajpgi.1997.273.4.G920","article-title":"Glucagon-like peptide-1 inhibits gastric emptying via vagal afferent-mediated central mechanisms","volume":"273","author":"mery\u00fcz","year":"1997","journal-title":"Am. J. Physiol. Gastrointest. Liver Physiol."},{"issue":"14","key":"10.1016\/j.biomaterials.2020.120250_bib40","doi-asserted-by":"crossref","first-page":"4812","DOI":"10.1523\/JNEUROSCI.6326-11.2012","article-title":"The glucagon-like peptide 1 (GLP-1) analogue, exendin-4, decreases the rewarding value of food: a new role for mesolimbic GLP-1 receptors","volume":"32","author":"Dickson","year":"2012","journal-title":"J. Neurosci."},{"issue":"1\u20132","key":"10.1016\/j.biomaterials.2020.120250_bib41","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1385\/JMN:18:1-2:07","article-title":"Interactions of glucagon-like peptide-1 (GLP-1) with the blood-brain barrier","volume":"18","author":"Kastin","year":"2002","journal-title":"J. Mol. Neurosci."},{"issue":"3","key":"10.1016\/j.biomaterials.2020.120250_bib42","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1038\/sj.ijo.0802206","article-title":"Entry of exendin-4 into brain is rapid but may be limited at high doses","volume":"27","author":"Kastin","year":"2003","journal-title":"Int. J. Obes."},{"issue":"8","key":"10.1016\/j.biomaterials.2020.120250_bib43","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.1097\/00001756-199906030-00004","article-title":"Glucagon-like peptide-1 modulates neuronal activity in the rat's hippocampus","volume":"10","author":"Oka","year":"1999","journal-title":"Neuroreport"},{"issue":"1","key":"10.1016\/j.biomaterials.2020.120250_bib44","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.bbr.2009.06.035","article-title":"Impairment of synaptic plasticity and memory formation in GLP-1 receptor KO mice: interaction between type 2 diabetes and Alzheimer's disease","volume":"205","author":"Abbas","year":"2009","journal-title":"Behav. Brain Res."},{"issue":"9","key":"10.1016\/j.biomaterials.2020.120250_bib45","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1038\/nm919","article-title":"Glucagon-like peptide-1 receptor is involved in learning and neuroprotection","volume":"9","author":"During","year":"2003","journal-title":"Nat. Med."},{"issue":"3","key":"10.1016\/j.biomaterials.2020.120250_bib46","doi-asserted-by":"crossref","first-page":"793","DOI":"10.3233\/JAD-190237","article-title":"Exenatide reverts the high-fat-diet-induced impairment of BDNF signaling and inflammatory response in an animal model of Alzheimer's disease","volume":"70","author":"Bomba","year":"2019","journal-title":"J. Alzheim. Dis."},{"issue":"15","key":"10.1016\/j.biomaterials.2020.120250_bib47","doi-asserted-by":"crossref","first-page":"3466","DOI":"10.1021\/jf403286w","article-title":"Resveratrol attenuates high-fat diet-induced disruption of the blood-brain barrier and protects brain neurons from apoptotic insults","volume":"62","author":"Chang","year":"2014","journal-title":"J. Agric. Food Chem."},{"issue":"7","key":"10.1016\/j.biomaterials.2020.120250_bib48","article-title":"The albumin-binding domain as a scaffold for protein engineering","volume":"6","author":"Nilvebrant","year":"2013","journal-title":"Comput. Struct. Biotechnol. J."},{"issue":"2\u20133","key":"10.1016\/j.biomaterials.2020.120250_bib49","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/j.regpep.2011.02.008","article-title":"A 4-arm polyethylene glycol derivative conjugated with exendin-4 peptide and palmitylamine having dual-function of size-increase and albumin-binding for long hypoglycemic action","volume":"167","author":"Kim","year":"2011","journal-title":"Regul. Pept."},{"issue":"1","key":"10.1016\/j.biomaterials.2020.120250_bib50","doi-asserted-by":"crossref","first-page":"93","DOI":"10.7150\/thno.12766","article-title":"Feasibility of affibody molecule-based PNA-mediated radionuclide pretargeting of malignant tumors","volume":"6","author":"Honarvar","year":"2016","journal-title":"Theranostics"},{"issue":"7","key":"10.1016\/j.biomaterials.2020.120250_bib51","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.2967\/jnumed.118.208348","article-title":"Radionuclide therapy of HER2-expressing human xenografts using affibody-based peptide nucleic acid\u2013mediated pretargeting: in vivo proof of principle","volume":"59","author":"Westerlund","year":"2018","journal-title":"J. Nucl. Med."}],"container-title":["Biomaterials"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0142961220304968?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0142961220304968?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,26]],"date-time":"2025-09-26T16:53:29Z","timestamp":1758905609000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0142961220304968"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10]]},"references-count":51,"alternative-id":["S0142961220304968"],"URL":"https:\/\/doi.org\/10.1016\/j.biomaterials.2020.120250","relation":{},"ISSN":["0142-9612"],"issn-type":[{"value":"0142-9612","type":"print"}],"subject":[],"published":{"date-parts":[[2020,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Genetic engineering of novel super long-acting Exendin-4 chimeric protein for effective treatment of metabolic and cognitive complications of obesity","name":"articletitle","label":"Article Title"},{"value":"Biomaterials","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biomaterials.2020.120250","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"120250"}}